

L20 ANSWER 37 OF 47 USPATFULL

ACCESSION NUMBER: 91:52474 USPATFULL

TITLE: Threshold ligand-receptor assay

INVENTOR(S): Buechler, Kenneth F., Santee, CA, United States
Valkirs, Gunars E., Escondido, CA, United States
Anderson, Richard R., Encinitas, CA, United States

PATENT ASSIGNEE(S): Biosite Diagnostics, Inc., San Diego, CA, United States

(U.S. corporation)

	NUMBER	KIND	DATE	
	-----	-----	-----	
PATENT INFORMATION:	US 5028535		19910702	<--
APPLICATION INFO.:	US 1989-295568		19890110 (7)	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Warden, Robert J.			
ASSISTANT EXAMINER:	Spiegel, Carol A.			
LEGAL REPRESENTATIVE:	Consalvi, Mary S.			
NUMBER OF CLAIMS:	70			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)			
LINE COUNT:	2055			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				
PI	US 5028535	19910702		<--
SUMM	Reaction Phase - The phase normally containing the ligand analogue conjugate , e.g., hapt en-enzyme conjugate , and ligand receptor, e.g., an antibody.			
DETD	. . . drugs. Subsequent to the elicitation of an immune response,			
the	mice are sacrificed and the spleen cells are fused with myeloma cells to produce antibody secreting hybridoma cell lines. Further characterization of the antibodies derived from the cell lines is achieved. . .			

L2 ANSWER 21 OF 24 SCISEARCH COPYRIGHT 2003 ISI (R)

ACCESSION NUMBER: 92:103074 SCISEARCH

THE GENUINE ARTICLE: HD549

TITLE: CARRIER SEQUENCE SELECTION - ONE KEY TO SUCCESSFUL
VACCINES

AUTHOR: ETLINGER H M (Reprint)

CORPORATE SOURCE: F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES NEW TECHNOL,
CH-4002 BASEL, SWITZERLAND (Reprint)

COUNTRY OF AUTHOR: SWITZERLAND

SOURCE: IMMUNOLOGY TODAY, (FEB 1992) Vol. 13, No. 2, pp.
52-55.

ISSN: 0167-4919.

DOCUMENT TYPE: Editorial; Journal

FILE SEGMENT: LIFE

LANGUAGE: ENGLISH

REFERENCE COUNT: 53

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The trend towards epitopic vaccines has brought with it the problem of ensuring carrier function, a role previously filled by carrier sequences of the attenuated organism. Here, Howard Etlinger proposes the use of carrier epitopes, derived from vaccines already in use and selected for their ability to activate only helper T-cell responses, in the administration of B-cell-specific epitopic vaccines.